$RCKT

$2.41▼ -30.55% YTD

8 SEC 13D/G filings tracked · Last updated Oct 30, 2026

Filing History

RCKT - Rocket Pharmaceuticals, Inc. - SEC Filing Update (30-OCT-2026) | ThinkSabio - Stocks Simplified

$2.41▼ -30.55%Oct 30, 2026 · ThinkSabio Blog

$RCKT SEC 13D/G institutional ownership filing. Healthcare sector. SEC Filing Update: #RCKT Rocket Pharmaceuticals, Inc. : $2.41 Sector: Healthcare |…

News

RCKT ▲ +1.6% - Rocket Pharmaceuticals, Inc.

CP $2.53▲ +1.6%Oct 7, 2026 · ThinkSabio Blog

$RCKT - Rocket Pharmaceuticals Highlights FDA-Aligned Pivotal Phase 2 Trial and Updated Clinical Findings for RP-A501 Following Danon Disease Investor…

News

RCKT ▲ +1.6% - Rocket Pharmaceuticals, Inc.

CP $2.53▲ +1.6%Oct 7, 2026 · ThinkSabio Blog

$RCKT Rocket Pharmaceuticals Highlights FDA-Aligned Pivotal Phase 2 Trial and Updated Clinical Findings for RP-A501 Following Danon Disease Investor W…

News

RCKT ▼ -3.4% - Rocket Pharmaceuticals, Inc.

CP $2.52▲ -3.4%Oct 6, 2026 · ThinkSabio Blog

$RCKT HTGC - Rocket Pharmaceuticals Secures Strategic Credit Facility for Up to $150 Million from Hercules Capital…

News

RCKT ▲ +4.1% - Rocket Pharmaceuticals, Inc.

CP $3.57▲ +4.1%Sep 15, 2026 · ThinkSabio Blog

$RCKT - Rocket Pharmaceuticals Announces FDA Alignment on Path to Complete Pivotal Phase 2 Trial of RP-A501 in Danon Disease…

News

RCKT ▲ +0.6% - Rocket Pharmaceuticals, Inc.

CP $3.45▲ +0.6%Sep 15, 2026 · ThinkSabio Blog

$RCKT Rocket Pharmaceuticals Announces FDA Alignment on Path to Complete Pivotal Phase 2 Trial of RP-A501 in Danon Disease…

News

RCKT ▼ -0.5% - Rocket Pharmaceuticals, Inc.

CP $3.84▲ -0.5%Sep 3, 2026 · ThinkSabio Blog

$RCKT - Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences…

SEC 13D/G

$RCKT SEC Filing Update (31-JUL-2026) | ThinkSabio - Stocks Simplified

$3.09▼ -10.95%Jul 31, 2026 · ThinkSabio Blog

$RCKT SEC 13D/G institutional ownership filing. Healthcare sector. SEC Filing Update: #RCKT : $3.09 Sector: Healthcare | YTD: 🔽 -10.95% The SEC disclo…